Background The aim was to evaluate the impact of discontinuation of imatinib in children in chronic phase of chronic myeloid leukemia (CML) and assess treatment free remission (TFR). Patients and methods: We performed a retrospective study in children diagnosed with CML chronic phase up to 18 ...
Approximately half of patients with chronic myeloid leukemia (CML) in sustained deep molecular response who discontinue tyrosine kinase inhibitors (TKIs) remain in treatment-free remission (TFR). Some of these patients have measurable residual disease (MRD) bymRNA testing, and most have detectableDNA...
LeukemiaSaussele S, Hehlmann R, Dietz C, et al. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML-study IV. ASH Annual Meeting 2014; session 632: abstract 155. En: http://www.bloodjournal.org/content/124/21/155; consul- tado ...
Chronic Myelogenous Leukemia Introduction Chronic myelogenous leukemia(CML), or chronic myeloidleukemia, is amyeloproliferative diseasecharacterized by an increase in the number ofneutrophilsand their precursors in the peripheral blood, with increased cellularity of the marrow as a result of an excess ofgr...
Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. It accounts for 20% o
Treatment-free remission in patients with chronic myeloid leukemia. Int J Hematol. 2018;. https://doi. org/10.1007/s12185-017-2295-0.Delphine, Rea,Jean-Michel,etc.Treatment-free remission in patients with chronic myeloid leukemia.[J].2017,(Spec)....
Chronic myeloid leukemia (CML) is the abnormal growth of relatively mature myeloid (white blood) cells. Half of all patients with CML are diagnosed after the age of 67. CML is associated with a chromosomal abnormality in which genetic material from chromosome 9 is transferred to chromosome 22....
Chronic myeloid leukemia (CML) is characterized by abnormal proliferation of myeloid cells which when untreated leads to bone marrow failure. Imatinib mesylate (IM) is the first line of therapy for treatment of CML and results in remission in most cases. However, a significant percentage of patien...
Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs), approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and remain in treatment-free remission (TFR). The ALLG CML8 study enrolled 40 imatinib-treated patients with undetectable BC...
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study 2019, The Lancet Haematology Citation Excerpt : The development of the BCR-ABL1 tyrosine kinase inhibitors (TK...